Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pathology

Decoding Your Pathology and Molecular Testing

At a Glance

Rare thyroid cancers require expert pathology review and Next-Generation Sequencing (NGS) to identify specific DNA mutations like BRAF or RET. Understanding your pathology and molecular reports is essential for ensuring an accurate diagnosis and accessing effective targeted precision therapies.

Navigating a rare thyroid cancer diagnosis requires looking beyond the basic “cancer” label. To get the most accurate treatment, you must understand two distinct types of reports: the Pathology Report (which describes what the cells look like) and the Molecular/Genomic Report (which describes the DNA mutations driving the growth) [1][2].

Why Expert Review is Essential

Rare thyroid cancers—like Anaplastic (ATC), Medullary (MTC), and Poorly Differentiated (PDTC)—are notoriously difficult to diagnose. Their appearance under a microscope can mimic other, more common conditions [3][4]. Because these cancers are rare, a general pathologist at a community hospital may only see a few cases in their entire career.

It is highly recommended to have your slides reviewed by an expert endocrine pathologist at a high-volume cancer center [5][6]. A second opinion can often refine the diagnosis, which may completely change your treatment plan [5].

Immunohistochemistry (IHC) vs. NGS

Your reports will likely mention two different types of laboratory testing:

  • Immunohistochemistry (IHC): Think of this as a “stain” test. Pathologists apply special dyes to your tissue sample to see if certain proteins are present [7]. For example, a positive Calcitonin stain helps confirm Medullary Thyroid Cancer [8].
  • Next-Generation Sequencing (NGS): This is a high-tech “DNA deep dive.” It looks at the actual genetic code of the tumor to find specific mutations that IHC cannot see [9][10]. NGS is now considered essential for rare thyroid cancers because it identifies “actionable” targets for precision drugs [11][12].

Key Mutations to Look For

Your NGS report will list several genes. Here is what they often mean for rare types:

  • ATC & PDTC: Look for BRAF V600E (a major target for specific drugs), TERT (often linked to more aggressive behavior), and TP53 (a gene that normally prevents cancer but is often “broken” in ATC) [13][14][15].
  • MTC: Look for RET mutations. These are the primary drivers of MTC and can be targeted with highly effective new medications [16][17].

The MTC Blood Markers: Calcitonin & CEA

If you have Medullary Thyroid Cancer, your doctor will use two main blood markers to monitor the disease [8]:

  • Calcitonin: A hormone made by the cancer cells. It is the most sensitive way to track the tumor’s activity [8][18].
  • CEA (Carcinoembryonic Antigen): A protein that acts as a backup marker. If CEA rises while Calcitonin stays stable, it can sometimes mean the cancer is becoming more aggressive [18][19].

Completeness Checklist for Your Reports

Ensure your records include the following details:

  • [ ] Expert Review: Was the report signed or reviewed by an endocrine/head and neck specialist?
  • [ ] Mitotic Index: A measure of how many cells are actively dividing (e.g., “3 per 2 mm²”) [20][4].
  • [ ] Vascular/Capsular Invasion: Did the cancer break through the thyroid’s outer “shell” or enter the blood vessels? [21][22]
  • [ ] NGS Results: Does the report list specific mutations (BRAF, RET, TERT, RAS, NTRK, etc.)? [9]
  • [ ] Resection Margins: If you had surgery, were the edges of the removed tissue clear of cancer cells?

Common questions in this guide

Why is a second opinion important for rare thyroid cancer pathology?
Rare thyroid cancers like anaplastic and medullary can mimic other more common conditions under a microscope. An expert endocrine pathologist at a high-volume cancer center has the specialized experience needed to confirm your diagnosis, which can significantly alter your treatment plan.
What is the difference between IHC and NGS testing?
Immunohistochemistry (IHC) uses special dyes on your tissue sample to detect specific proteins, such as calcitonin. Next-Generation Sequencing (NGS) analyzes the tumor's DNA to identify specific genetic mutations that IHC cannot see, which is crucial for finding targeted treatment options.
What mutations should I look for on my Next-Generation Sequencing (NGS) report?
For anaplastic and poorly differentiated thyroid cancers, key mutations include BRAF V600E, TERT, and TP53. If you have medullary thyroid cancer, RET mutations are the primary drivers and can often be treated with highly effective targeted medications.
What are Calcitonin and CEA blood markers used for?
Calcitonin is a hormone produced by medullary thyroid cancer cells and is the most sensitive blood test to track tumor activity. CEA is a backup marker; if CEA rises while Calcitonin stays stable, it may indicate the cancer is behaving more aggressively.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my pathology been reviewed by a specialized endocrine pathologist at a high-volume center?
  2. 2.What was my mitotic index and were there any signs of vascular or capsular invasion in my tumor?
  3. 3.Which NGS panel was used for my testing, and does it cover mutations like BRAF, RET, TERT, and TP53?
  4. 4.If I have MTC, what are my baseline Calcitonin and CEA levels, and how often will we monitor them to calculate 'doubling time'?
  5. 5.Does my pathology report mention any IHC markers like Calcitonin, Chromogranin A, or PAX8?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Overview of the 2022 WHO Classification of Thyroid Neoplasms.

    Baloch ZW, Asa SL, Barletta JA, et al.

    Endocrine pathology 2022; (33(1)):27-63 doi:10.1007/s12022-022-09707-3.

    PMID: 35288841
  2. 2

    SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.

    Ruz-Caracuel I, Alonso-Gordoa T, Hernández S, et al.

    Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(2)):100859 doi:10.1016/j.patol.2026.100859.

    PMID: 41747300
  3. 3

    Insights into Thyroid and Salivary Gland Cytopathology: Highlights from a 45th European Congress of Cytology Slide Seminar.

    Brochard C, Kowalewski A, Vigliar E, et al.

    Acta cytologica 2025; (69(2)):171-182 doi:10.1159/000543225.

    PMID: 39701044
  4. 4

    Fine needle aspiration cytology features of poorly differentiated thyroid carcinoma.

    Purkait S, Agarwal S, Mathur SR, et al.

    Cytopathology : official journal of the British Society for Clinical Cytology 2016; (27(3)):176-84 doi:10.1111/cyt.12270.

    PMID: 26662642
  5. 5

    Liver Mass as First-Time Diagnosis of Sarcomatoid Anaplastic Thyroid Carcinoma: A Rare Malignancy Presenting at an Unexpected Body Site.

    Kamashki A, Rivera M, Sturgis CD

    The American journal of case reports 2023; (24()):e941838 doi:10.12659/AJCR.941838.

    PMID: 38041397
  6. 6

    An Overview on Prevalence and Detection Approaches of BRAF V600E Mutation in Anaplastic Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

    Behnagh AK, Eghbali M, Abdolmaleki F, et al.

    Iranian journal of public health 2024; (53(7)):1496-1507 doi:10.18502/ijph.v53i7.16044.

    PMID: 39086414
  7. 7

    The Role of CD56, HBME-1, and CK19 Immunohistochemical Markers in the differential Diagnosing of Thyroid Neoplasms.

    Chandrakumari AS, Singaravelu SLD, Sinha P

    Nigerian medical journal : journal of the Nigeria Medical Association 2024; (65(5)):716-724 doi:10.60787/nmj-v65i3.509.

    PMID: 39633686
  8. 8

    "Triple-negative" non-secretory medullary thyroid cancer: uncommon pathological findings in a rare disease.

    Martínez-Montoro JI, Gómez-Pérez AM, Gallego E, et al.

    Archives of medical science : AMS 2022; (18(3)):825-828 doi:10.5114/aoms/147431.

    PMID: 35591839
  9. 9

    Mutational Profiling Detection in FNAC Samples of Different Types of Thyroid Neoplasms Using Targeted NGS.

    Liang R, Luo M, Yang X, et al.

    Cancers 2025; (17(15)) doi:10.3390/cancers17152429.

    PMID: 40805132
  10. 10

    Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

    Waguespack SG, Drilon A, Lin JJ, et al.

    European journal of endocrinology 2022; (186(6)):631-643 doi:10.1530/EJE-21-1259.

    PMID: 35333737
  11. 11

    Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management.

    Mete O, Boucher A, Schrader KA, et al.

    Endocrine pathology 2024; (35(4)):293-308 doi:10.1007/s12022-024-09836-x.

    PMID: 39579327
  12. 12

    Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

    Khan SA, Ci B, Xie Y, et al.

    Head & neck 2019; (41(6)):1928-1934 doi:10.1002/hed.25634.

    PMID: 30758123
  13. 13

    Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

    Subbiah V, Kreitman RJ, Wainberg ZA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(1)):7-13 doi:10.1200/JCO.2017.73.6785.

    PMID: 29072975
  14. 14

    Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan.

    Toda S, Hiroshima Y, Iwasaki H, Masudo K

    The Journal of clinical endocrinology and metabolism 2024; (109(11)):2784-2792 doi:10.1210/clinem/dgae271.

    PMID: 38630010
  15. 15

    Current status of the prognostic molecular markers in medullary thyroid carcinoma.

    Oczko-Wojciechowska M, Czarniecka A, Gawlik T, et al.

    Endocrine connections 2020; (9(12)):R251-R263.

    PMID: 33112827
  16. 16

    Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.

    Hadoux J, Elisei R, Brose MS, et al.

    The New England journal of medicine 2023; (389(20)):1851-1861 doi:10.1056/NEJMoa2309719.

    PMID: 37870969
  17. 17

    Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

    Wirth LJ, Sherman E, Robinson B, et al.

    The New England journal of medicine 2020; (383(9)):825-835 doi:10.1056/NEJMoa2005651.

    PMID: 32846061
  18. 18

    Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.

    Liu S, Zhao H, Li X

    Cancer management and research 2024; (16()):299-310 doi:10.2147/CMAR.S440477.

    PMID: 38617188
  19. 19

    Small cell medullary thyroid carcinoma: A diagnostic dilemma.

    Verma A, Kane S, Vinarkar S, D'Cruz AK

    Indian journal of pathology & microbiology 2017; (60(4)):562-564 doi:10.4103/IJPM.IJPM_187_17.

    PMID: 29323074
  20. 20

    Papillary thyroid carcinoma tall cell subtype (PTC-TC) and high-grade differentiated thyroid carcinoma tall cell phenotype (HGDTC-TC) have different clinical behaviour: a retrospective study of 1456 patients.

    Ghossein R, Katabi N, Dogan S, et al.

    Histopathology 2024; (84(7)):1130-1138 doi:10.1111/his.15157.

    PMID: 38528726
  21. 21

    The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.

    Moon S, Song YS, Jung KY, et al.

    Endocrinology and metabolism (Seoul, Korea) 2025; (40(3)):357-384 doi:10.3803/EnM.2025.2465.

    PMID: 40598904
  22. 22

    Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma.

    Wong KS, Lorch JH, Alexander EK, et al.

    Thyroid : official journal of the American Thyroid Association 2019; (29(9)):1255-1261 doi:10.1089/thy.2019.0263.

    PMID: 31397224

This page explains pathology and molecular testing terminology for rare thyroid cancers for educational purposes only. Your pathologist and oncologist are the best sources for interpreting your specific laboratory reports.

Get notified when new evidence is published on Rare thyroid carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.